Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $88 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals sees FY26 revenue $630M-$650M, consensus $595.94M
- Mirum Pharmaceuticals reports preliminary Q4 revenue $149M, consensus $135.72M
- Mirum Pharmaceuticals Announces Strong 2025 Sales and 2026 Outlook
- Mirum Files Patent Suits to Block Livmarli Generics
- Mirum Pharmaceuticals Raises Capital via Private Placement